Skip to main content
Year archive

Ascletis Pharma Inc. — 2022 filings

All 127 regulatory filings released by Ascletis Pharma Inc. (1672) in 2022, sourced directly from the official regulator.

127 Filings
2022 Period
2022 filings (127)
Filing Released Lang
GRANT OF SHARE OPTIONS
Regulatory Filings
2022-12-30 English
VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES NOTICE OF ISSUANCE OF THE U.S. PATENT FOR ORAL VIRAL INHIBITOR ASC10 AND ITS DERIVATIVES
Regulatory Filings
2022-12-19 English
VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES POSITIVE PHASE I CLINICAL RESULTS OF ORAL RDRP INHIBITOR ASC10 FOR COVID-19
Regulatory Filings
2022-12-12 English
Remuneration Committee - Terms of Reference
Regulatory Filings
2022-12-08 English
VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES IND APPROVAL OF ORAL 3CLPRO INHIBITOR ASC11 FOR COVID-19 BY CHINA NMPA
Regulatory Filings
2022-12-07 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2022
Regulatory Filings
2022-12-02 English
Monthly Return of Equity Issuer on movements in Securities for the month ended 30 November 2022
Regulatory Filings
2022-12-01 English
VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES COMPLETION OF 180 PATIENT ENROLLMENT FOR PHASE II CLINICAL TRIAL OF FASN INHIBITOR ASC40 FOR ACNE
Regulatory Filings
2022-11-30 English
VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES IND FILING OF ORAL 3CLPRO INHIBITOR ASC11 FOR COVID-19 ACCEPTED BY CHINA NMPA
Regulatory Filings
2022-11-29 English
VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES IND APPROVAL OF ORAL 3CLPRO INHIBITOR ASC11 FOR COVID-19 BY U.S. FDA
Regulatory Filings
2022-11-23 English
VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES IND APPROVAL OF ORAL PD-L1 SMALL MOLECULE INHIBITOR ASC61 FOR TREATMENT OF ADVANCED SOLID TUMORS BY CHINA NMPA
Regulatory Filings
2022-11-17 English
VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES IND APPROVAL OF ASC10 FOR MONKEYPOX INDICATION BY U.S. FDA
Regulatory Filings
2022-11-16 English
VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES POSTER PRESENTATION OF PHASE I, SINGLE-DOSE STUDY OF ASC43F FOR NASH AT AASLD ANNUAL MEETING 2022
Regulatory Filings
2022-11-07 English
Next Day Disclosure Return
Regulatory Filings
2022-11-04 English
VOLUNTARY ANNOUNCEMENT - ASCLETIS'STRATEGIC PARTNER SAGIMET BIOSCIENCES ANNOUNCES POSITIVE INTERIM PHASE 2B CLINICAL TRIAL DATA WITH ASC40 (DENIFANSTAT), A FIRST-IN-CLASS FATTY ACID SYNTHASE INH
Regulatory Filings
2022-11-04 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2022
Regulatory Filings
2022-11-03 English
VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES U.S. IND FILING OF ORAL 3CLPRO INHIBITOR ASC11 FOR COVID-19
Regulatory Filings
2022-11-02 English
Monthly Return of Equity Issuer on movements in Securities for the month ended 31 October 2022
Regulatory Filings
2022-11-01 English
INSIDE INFORMATION - ASCLETIS ANNOUNCES SIGNING LICENSE AND SUPPLY AGREEMENT OF RITONAVIR FOR COVID-19 DRUG PAXLOVID TM IN MAINLAND CHINA WITH PFIZER
Regulatory Filings
2022-10-28 English
VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES U.S. IND FILING OF ORAL ANTIVIRAL ASC10 FOR MONKEYPOX INDICATION
Regulatory Filings
2022-10-26 English
DISCLOSEABLE TRANSACTION DISPOSAL OF LAND USE RIGHTS AND BUILDINGS
Regulatory Filings
2022-10-14 English
VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES DOSING OF 24 HEALTHY SUBJECTS OF THE FIRST 3 COHORTS IN MULTIPLE-DOSE ESCALATION PHASE I CLINICAL TRIAL OF ORAL RDRP INHIBITOR ASC10 FOR COVID-19
Regulatory Filings
2022-10-10 English
Monthly Return of Equity Issuer on movements in Securities for the month ended 30 September 2022
Regulatory Filings
2022-10-05 English
VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES DOSING OF THE FIRST PATIENT IN PHASE II CLINICAL TRIAL OF THR-BETA AGONIST ASC41 FOR 52-WEEK TREATMENT OF LIVER BIOPSY-PROVEN NASH
Regulatory Filings
2022-10-05 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2022
Regulatory Filings
2022-09-30 English
VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES DOSING OF THE FIRST PATIENT IN THE PHASE IIb EXPANSION COHORT OF ASC22 (ENVAFOLIMAB) FOR CHRONIC HEPATITIS B FUNCTIONAL CURE
Regulatory Filings
2022-09-28 English
Notification Letter with Request Form to Non-Registered Holders of Shares - Notice of Publication of Interim Report 2022
Regulatory Filings
2022-09-27 English
Interim Report 2022
Regulatory Filings
2022-09-27 English
INTERIM REPORT 2022
Regulatory Filings
2022-09-21 English
VOLUNTARY ANNOUNCEMENT - BUSINESS UPDATE
Regulatory Filings
2022-09-16 English
VOLUNTARY ANNOUNCEMENT - SHANGHAI PUBLIC HEALTH CLINICAL CENTER COMPLETED PATIENT ENROLLMENT IN CLINICAL STUDY OF PD-L1 ANTIBODY ASC22 (ENVAFOLIMAB) IN COMBINATION WITH CHIDAMIDE FOR FUNCTIONAL CURE O
Regulatory Filings
2022-09-15 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2022
Regulatory Filings
2022-09-02 English
Monthly Return of Equity Issuer on movements in Securities for the month ended 31 August 2022
Regulatory Filings
2022-09-01 English
ANNOUNCEMENT OF INTERIM RESULTS 2022
Regulatory Filings
2022-08-28 English
CLARIFICATION ANNOUNCEMENT IN RELATION TO THE CHANGE OF COMPANY SECRETARY AND AUTHORISED REPRESENTATIVES
Regulatory Filings
2022-08-24 English
CHANGE OF COMPANY SECRETARY AND AUTHORISED REPRESENTATIVES
Regulatory Filings
2022-08-22 English
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2022
Regulatory Filings
2022-08-22 English
VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES IND APPROVAL OF ORAL RDRP INHIBITOR ASC10 FOR COVID-19 BY CHINA NMPA
Regulatory Filings
2022-08-22 English
DATE OF BOARD MEETING
Regulatory Filings
2022-08-16 English
VOLUNTARY ANNOUNCEMENT - GANNEX ANNOUNCES FIRST SUBJECT DOSED IN THE U.S. DRUG-DRUG INTERACTION STUDY OF FXR AGONIST ASC42 FOR TREATMENT OF PRIMARY BILIARY CHOLANGITIS
Regulatory Filings
2022-08-16 English
VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES FIRST PATIENT DOSED IN THE U.S. PHASE I CLINICAL TRIAL OF ORAL PD-L1 SMALL MOLECULE INHIBITOR PRODRUG ASC61 FOR TREATMENT OF ADVANCED SOLID TUMORS
Regulatory Filings
2022-08-08 English
VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES IND FILING OF ORAL RDRP INHIBITOR ASC10 FOR COVID-19 ACCEPTED BY CHINA NMPA
Regulatory Filings
2022-08-04 English
VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES FDA CLEARANCE OF ORAL RDRP INHIBITOR ASC10 TO CONDUCT A RANDOMIZED, PLACEBO CONTROLLED PHASE Ib STUDY IN MILD-TO-MODERATE COVID-19 PATIENTS
Regulatory Filings
2022-08-03 English
Monthly Return of Equity Issuer on movements in Securities for the month ended 31 July 2022
Regulatory Filings
2022-08-02 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2022
Regulatory Filings
2022-08-02 English
NOTICE OF BOARD MEETING
Regulatory Filings
2022-07-27 English
AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION
Regulatory Filings
2022-07-26 English
CHANGE OF ADDRESS OF HONG KONG BRANCH SHARE REGISTRAR AND TRANSFER OFFICE
Regulatory Filings
2022-07-22 English
VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES U.S. IND FILING OF ORAL RDRP INHIBITOR DRUG CANDIDATE ASC10 FOR COVID-19
Regulatory Filings
2022-07-06 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2022
Regulatory Filings
2022-07-05 English
Monthly Return of Equity Issuer on movements in Securities for the month ended 30 June 2022
Regulatory Filings
2022-07-04 English
VOLUNTARY ANNOUNCEMENT - SHANGHAI PUBLIC HEALTH CLINICAL CENTER COMPLETED THE FIRST PATIENT DOSING IN CLINICAL STUDY OF PD-L1 ANTIBODY ASC22 IN COMBINATION WITH CHIDAMIDE FOR FUNCTIONAL CURE OF HIV I
Regulatory Filings
2022-07-04 English
GRANT OF SHARE OPTIONS
Regulatory Filings
2022-06-30 English
VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCED FIRST SUBJECT DOSED IN THE PHASE II CLINICAL TRIAL OF ASC22 (ENVAFOLIMAB) FOR IMMUNE RESTORATION/FUNCTIONAL CURE OF HIV-1 INFECTION
Regulatory Filings
2022-06-28 English
VOLUNTARY ANNOUNCEMENT - ASCLETIS' SUBCUTANEOUS PD-L1 ANTIBODY ASC22 DEMONSTRATED POTENTIAL OF FUNCTIONAL CURE OF CHRONIC HEPATITIS B AS 42.9% OF PATIENTS WITH BASELINE HBsAg LESS THAN OR EQUAL T
Regulatory Filings
2022-06-27 English
SECOND AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION
Regulatory Filings
2022-06-16 English
POLL RESULTS OF ANNUAL GENERAL MEETING HELD ON JUNE 16, 2022
Regulatory Filings
2022-06-16 English
VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES ORAL PRESENTATION ON UPDATES FROM PHASE IIB CLINICAL TRIAL OF ASC22, A SUBCUTANEOUS PD-L1 ANTIBODY FOR FUNCTIONAL CURE OF CHRONIC HEPATITIS B AT EASL ILC 20
Regulatory Filings
2022-06-16 English
AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION
Regulatory Filings
2022-06-14 English
POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 14 JUNE 2022
Regulatory Filings
2022-06-14 English
VOLUNTARY ANNOUNCEMENT - GANNEX ANNOUNCES U.S. FDA CLEARANCE OF CLINICAL TRIAL ON FXR AGONIST ASC42 FOR TREATMENT OF PRIMARY BILIARY CHOLANGITIS
Regulatory Filings
2022-06-08 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2022
Regulatory Filings
2022-06-02 English
Monthly Return of Equity Issuer on movements in Securities for the month ended 31 May 2022
Regulatory Filings
2022-06-02 English
Notification Letter to Non-Registered Holders of Shares with Request Form - Notice of Publication of Circular containing Notice of Annual General Meeting
Regulatory Filings
2022-05-24 English
Notice of 2022 Annual General Meeting
Regulatory Filings
2022-05-24 English
Form of Proxy for the 2022 Annual General Meeting
Regulatory Filings
2022-05-24 English
Proposals for General Mandates to Issue Shares and to Repurchase Shares, Re-Election of Retiring Directors, Proposed Amendments to The Memorandum and Articles of Association and Notice of Annual Gener
Regulatory Filings
2022-05-24 English
PROPOSED ADOPTION OF AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION
Regulatory Filings
2022-05-19 English
VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES U.S. IND APPROVAL OF ASC22 (ENVAFOLIMAB) FOR IMMUNE RESTORATION/FUNCTIONAL CURE OF HIV-1 INFECTED PATIENTS
Regulatory Filings
2022-05-11 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2022
Regulatory Filings
2022-05-05 English
Monthly Return of Equity Issuer on movements in Securities for the month ended 30 April 2022
Regulatory Filings
2022-05-03 English
SUPPLEMENTAL ANNOUNCEMENT TO THE CIRCULAR OF THE COMPANY DATED 26 APRIL 2022
Regulatory Filings
2022-04-29 English
NOTICE OF ANNUAL GENERAL MEETING
Regulatory Filings
2022-04-25 English
GENERAL MANDATES TO ISSUE AND REPURCHASE SHARES, RE-ELECTION OF RETIRING DIRECTORS, PROPOSED ADOPTION OF THE AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION AND NOTICE OF ANNUAL GENERAL ME
Regulatory Filings
2022-04-25 English
Annual Report 2021
Regulatory Filings
2022-04-25 English
FORM OF PROXY FOR ANNUAL GENERAL MEETING (or any adjournment thereof)
Regulatory Filings
2022-04-25 English
PROPOSED ADOPTION OF NEW MEMORANDUM AND ARTICLES OF ASSOCIATION
Regulatory Filings
2022-04-20 English
Notification Letter to Non-Registered Holders of Shares with Request Form - Notice of Publication of Annual Report 2021
Regulatory Filings
2022-04-20 English
Annual Report 2021
Regulatory Filings
2022-04-20 English
INSIDE INFORMATION - BUSINESS UPDATE: 3CLPRO INHIBITOR ASC11 DEMONSTRATED POTENTIAL TO BE EFFECTIVE TREATMENT FOR COVID-19
Regulatory Filings
2022-04-19 English
INSIDE INFORMATION - ASCLETIS ANNOUNCES COOPERATION WITH CHINA MEHECO INTERNATIONAL CO., LTD. IN DISTRIBUTION OF ITS RITONAVIR TABLETS IN CHINESE MAINLAND
Regulatory Filings
2022-04-13 English
VOLUNTARY ANNOUNCEMENT - GANNEX ANNOUNCES FIRST PATIENT DOSED IN PHASE II CLINICAL TRIAL OF ASC42, AN FXR AGONIST, FOR PRIMARY BILIARY CHOLANGITIS
Regulatory Filings
2022-04-10 English
POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON 7 APRIL 2022
Regulatory Filings
2022-04-07 English
VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES CHINA IND APPROVAL OF ITS SECOND FASN INHIBITOR ASC60 FOR TREATMENT OF ADVANCED SOLID TUMORS
Regulatory Filings
2022-04-06 English
ANNOUNCEMENT - INSIDE INFORMATION - ASCLETIS ANNOUNCES COMPLETION OF FIRST SALE OF ITS RITONAVIR TABLETS IN ZHEJIANG PROVINCE
Regulatory Filings
2022-04-04 English
ANNOUNCEMENT - INSIDE INFORMATION - ASCLETIS ANNOUNCES SUBMISSION OF MARKETING AUTHORIZATION APPLICATION FOR RITONAVIR IN HONG KONG
Regulatory Filings
2022-04-03 English
Monthly Return of Equity Issuer on movements in Securities for the month ended 31 March 2022
Regulatory Filings
2022-04-01 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2022
Regulatory Filings
2022-04-01 English
GRANT OF SHARE OPTIONS
Regulatory Filings
2022-03-31 English
VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE II CLINICAL TRIAL OF ASC42, AN IN-HOUSE DEVELOPED, BEST-IN-CLASS FXR AGONIST FOR CHRONIC HEPATITIS B INDICATION
Regulatory Filings
2022-03-30 English
RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2021
Regulatory Filings
2022-03-29 English
VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES THE LATEST RESULTS OF THE PRECLINICAL STUDIES OF TWO NOVEL ANTI-CANCER DRUG CANDIDATES, ASC61 AND ASC60, TO BE PRESENTED AT AACR ANNUAL MEETING 2022
Regulatory Filings
2022-03-27 English
ANNUAL RESULTS OF ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2021
Regulatory Filings
2022-03-21 English
DATE OF BOARD MEETING
Regulatory Filings
2022-03-17 English
VERY SUBSTANTIAL DISPOSAL AND VERY SUBSTANTIAL ACQUISITION IN RELATION TO LAND RESUMPTION
Regulatory Filings
2022-03-16 English
Proxy form for use at the Extraordinary General Meeting to be held with a combination of an in-room meeting at Flat C, 18th Floor, Bold Win Industrial Building, 16-18 Wah Sing Street, Kwai Chung, New
Regulatory Filings
2022-03-16 English
NOTICE OF EXTRAORDINARY GENERAL MEETING
Regulatory Filings
2022-03-16 English
VERY SUBSTANTIAL DISPOSAL AND VERY SUBSTANTIAL ACQUISITION IN RELATION TO LAND RESUMPTION
Regulatory Filings
2022-03-16 English
ANNOUNCEMENT - INSIDE INFORMATION - BUSINESS UPDATE ON ASC10, AN ORAL DOUBLE PRODRUG AGAINST COVID-19
Regulatory Filings
2022-03-15 English
ANNOUNCEMENT - INSIDE INFORMATION - ASCLETIS ANNOUNCES FURTHER EXPANSION OF RITONAVIR ORAL TABLET PRODUCTION CAPACITY TO 530 MILLION TABLETS PER YEAR
Regulatory Filings
2022-03-13 English
FURTHER DELAY IN DESPATCH OF CIRCULAR IN RESPECT OF VERY SUBSTANTIAL DISPOSAL AND VERY SUBSTANTIAL ACQUISITION IN RELATION TO LAND RESUMPTION
Regulatory Filings
2022-03-07 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2022
Regulatory Filings
2022-03-03 English
Monthly Return of Equity Issuer on movements in Securities for the month ended 28 February 2022
Regulatory Filings
2022-03-02 English
NOTICE OF BOARD MEETING
Regulatory Filings
2022-03-02 English
ANNOUNCEMENT - INSIDE INFORMATION - ASCLETIS ANNOUNCES SUBMISSION OF MARKETING AUTHORIZATION APPLICATIONS FOR RITONAVIR IN EIGHT ADDITIONAL EUROPEAN COUNTRIES
Regulatory Filings
2022-03-01 English
POSITIVE PROFIT ALERT
Regulatory Filings
2022-02-27 English
VOLUNTARY ANNOUNCEMENT - SHANGHAI PUBLIC HEALTH CLINICAL CENTER INITIATED FUNCTIONAL CURE STUDY OF ANTI-PD-L1 ANTIBODY ASC22 (ENVAFOLIMAB) IN COMBINATION WITH CHIDAMIDE IN HIV-INFECTED PATIENTS
Regulatory Filings
2022-02-14 English
ANNOUNCEMENT - INSIDE INFORMATION - ASCLETIS ANNOUNCES SUBMISSION OF MARKETING AUTHORIZATION APPLICATIONS FOR RITONAVIR IN MULTIPLE EUROPEAN COUNTRIES
Regulatory Filings
2022-02-13 English
ANNOUNCEMENT - INSIDE INFORMATION - ASCLETIS ANNOUNCES POSITIVE DATA OF ORAL DOUBLE PRODRUG ASC10 AND ITS ANTIVIRAL NUCLEOSIDE ANALOG ASC10-A AGAINST OMICRON VARIANT
Regulatory Filings
2022-02-07 English
VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES U.S. IND APPROVAL OF ORAL PD-L1 SMALL MOLECULE INHIBITOR ASC61 FOR TREATMENT OF ADVANCED SOLID TUMORS
Regulatory Filings
2022-02-06 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2022
Regulatory Filings
2022-02-04 English
Monthly Return of Equity Issuer on movements in Securities for the month ended 31 January 2022
Regulatory Filings
2022-02-04 English
VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES IND FILING OF ITS SECOND FASN INHIBITOR ASC60 FOR ADVANCED SOLID TUMORS ACCEPTED BY CHINA NMPA
Regulatory Filings
2022-01-26 English
VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES FIRST PATIENT DOSED IN THE PHASE III CLINICAL TRIAL OF FASN INHIBITOR ASC40 COMBINED WITH BEVACIZUMAB FOR TREATMENT OF RECURRENT GLIOBLASTOMA
Regulatory Filings
2022-01-23 English
FURTHER SUPPLEMENTAL ANNOUNCEMENT DISCLOSEABLE TRANSACTION IN RELATION TO LEASE AGREEMENT
Regulatory Filings
2022-01-20 English
SUPPLEMENTAL ANNOUNCEMENT DISCLOSEABLE TRANSACTION IN RELATION TO LEASE AGREEMENT
Regulatory Filings
2022-01-18 English
ANNOUNCEMENT - INSIDE INFORMATION - ASCLETIS ANNOUNCES SIGNING OF RITONAVIR TABLET PURCHASE AGREEMENT WITH PHOKAM PHARMACEUTICAL IMPORT-EXPORT CO., LTD OF LAOS
Regulatory Filings
2022-01-18 English
Next Day Disclosure Return
Regulatory Filings
2022-01-17 English
VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES U.S. IND APPROVAL OF ASC22 (ENVAFOLIMAB), A SUBCUTANEOUSLY ADMINISTERED PD-L1 ANTIBODY FOR FUNCTIONAL CURE OF CHRONIC HEPATITIS B
Regulatory Filings
2022-01-17 English
DISCLOSEABLE TRANSACTION IN RELATION OF THE LEASE AGREEMENT
Regulatory Filings
2022-01-14 English
VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES FIRST PATIENT DOSED IN THE PHASE II CLINICAL TRIAL OF FASN INHIBITOR ASC40 FOR TREATMENT OF MODERATE TO SEVERE ACNE
Regulatory Filings
2022-01-13 English
VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES FIRST PATIENT DOSED IN THE PHASE II CLINICAL TRIAL OF ASC42, AN IN-HOUSE DEVELOPED, BEST-IN-CLASS FXR AGONIST FOR CHRONIC HEPATITIS B INDICATION
Regulatory Filings
2022-01-11 English
VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES U.S. IND FILING FOR IN-HOUSE DEVELOPED ORAL PD-L1 SMALL MOLECULE INHIBITOR ASC61 FOR TREATMENT OF ADVANCED SOLID TUMORS
Regulatory Filings
2022-01-10 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2021
Regulatory Filings
2022-01-05 English
VOLUNTARY ANNOUNCEMENT - GANNEX ANNOUNCES COMPLETION OF THE U.S. PHASE I TRIAL OF ASC43F, AN IN-HOUSE DEVELOPED FIRST-IN-CLASS DUAL TARGETING FIXED-DOSE COMBINATION TABLET FOR NASH
Regulatory Filings
2022-01-04 English
Monthly Return of Equity Issuer on movements in Securities for the month ended 31 December 2021
Regulatory Filings
2022-01-03 English
ANNOUNCEMENT - INSIDE INFORMATION - ASCLETIS EXPANDS RITONAVIR ORAL TABLET PRODUCTION AND ANNOUNCES ORAL DIRECT-ACTING ANTIVIRAL PIPELINE AGAINST SARS-COV-2 VIRUS
Regulatory Filings
2022-01-03 English